)
Investigating biomarkers of recurrence in glioblastoma
Project Title: Investigating biomarkers of recurrence in glioblastoma
Project Duration: 2022-
MOHCCN Consortium: Princess Margaret Cancer Consortium
Investigators: Dr. Teresa Purzner, Dr. Amber Simpson, Dr. Lillian Siu; Dr. Harriet Feilotter, Dr. David Berman
Partners:
- Princess Margaret Cancer Centre
- Kingston Health Sciences Centres
- Queen's University
- The Centre for Health Innovation
- OICR
- Queen's Cancer Research Institute
Aim/goals:
- To investigate biomarkers of recurrence in glioblastomas
Summary:
We will be investigating biomarkers of recurrence in glioblastomas (GBMs) through high-density, 3D image guided biopsies of the tumor bed following gross total resection. Patients will be followed until the time of recurrence. Once recurrence is radiographically confirmed, biopsies taken at the site of recurrence will undergo multi-modal characterization to identify markers of recurrence. In addition to genome and transcriptome sequencing, radiomics technology and artificial intelligence will be used to examine patterns in the data and provide predictions to use in decision support.